RNA serves as the essential intermediary in gene expression, translating genomic blueprints into proteins crucial for cellular function. In numerous genetic diseases, including Huntington’s disease and certain malignancies, aberrant RNA transcripts harbor errors or toxic repetitive elements that disrupt protein synthesis and cellular homeostasis. Traditional RNA editing methods often lack finesse; some indiscriminately degrade the entire RNA strand while others can only alter single nucleotides. These limitations have hampered the development of effective RNA-based therapeutics that can safely restore normal cellular activity. The complexity of accurately repairing long stretches of RNA without cellular toxicity has remained a formidable challenge until now.

Central to this breakthrough is the exploitation of the Cas13 enzyme, a member of the CRISPR family recently recognized for its RNA-targeting capabilities. Unlike its DNA-targeting counterparts, Cas13 operates as molecular scissors specialized in cleaving RNA strands. The researchers engineered Cas13 variants that display remarkably high precision, permitting the enzyme to pinpoint exact cut sites within RNA molecules. This specificity is critical to excising only the faulty RNA segments without compromising surrounding functional sequences, a necessity for therapeutic viability.

The team’s novel platform, RNA Segment Editing (RSE), integrates this enhanced Cas13 precision within a sophisticated system that mimics a ‘find and replace’ operation familiar from text editing software—but in a biological context. RSE identifies and snips out deleterious RNA segments before inserting a synthetic, healthy patch that reinstates normal RNA function. This approach allows dynamic and reversible RNA repair, conducted entirely within living cells, preserving their integrity and physiological function. The implications for treating neurodegenerative diseases characterized by toxic RNA products are profound.

Huntington’s disease exemplifies the potential applications of RSE. In this hereditary neurodegenerative disorder, expanded CAG repeats in the RNA transcript generate neurotoxic polyglutamine stretches within proteins, leading to progressive neuronal cell death. Existing experimental therapies attempting to eliminate the entire mutant RNA often inadvertently disrupt normal protein production, risking unintended side effects. RSE’s capacity for targeted segment removal ensures that only harmful repetitive regions are excised, safeguarding the functional portions of RNA and maintaining essential cellular processes.

Professor Kwon Sung Chul, the study’s principal investigator and an Assistant Professor at HKUMed, emphasizes the therapeutic promise of this technology: “Our objective is to develop an RNA editing tool that enables programmable repair without introducing permanent changes to the patient’s DNA. RSE offers a flexible and safe method for precise RNA correction, which can be paused or reversed by simply halting treatment—similar in convenience and control to conventional pharmacological interventions.” Such adaptability is a major advantage over irreversible genome editing techniques, enhancing safety for clinical applications.

The utilization of engineered Cas13 and RSE also addresses challenges encountered by RNA interference and antisense oligonucleotides, which sometimes trigger immune responses or non-specific gene silencing. By focusing on segment-specific editing rather than wholesale RNA degradation or single-nucleotide modification, the RSE platform reduces off-target effects and minimizes cellular stress. This level of control is vital to the successful treatment of chronic neurodegenerative conditions that require sustained therapeutic intervention.

In addition to Huntington’s disease, the conceptual framework of RSE presents opportunities to target RNA abnormalities implicated in other neurological disorders, such as Amyotrophic Lateral Sclerosis (ALS) and certain inherited ataxias, where pathogenic RNA repeat expansions or structured RNA motifs disrupt normal neuronal function. The potential to customize RNA patches for diverse pathogenic sequences underscores the broad applicability of this breakthrough.

From a technical standpoint, the design of RSE involves sophisticated guide RNAs that direct the engineered Cas13 to precise RNA sequences. These guides facilitate recognition and cleavage of specific RNA segments, while synthetic RNA patches are introduced to seamlessly replace excised regions through cellular RNA repair mechanisms. This approach demands exact molecular coordination and signal regulation to avoid unintended cleavage, a challenge the team overcame through iterative optimization and biochemical validation.

The research team further demonstrated the efficacy and safety of RSE in cellular models, verifying the accurate editing of pathogenic RNA without adverse effects on cell viability or gene expression integrity. These encouraging preclinical results set the stage for future in vivo studies and the potential translation into therapeutic modalities. The adaptability of RSE to existing delivery systems, such as lipid nanoparticles or viral vectors, expands its clinical feasibility.

Published in the prestigious journal Nature Communications, the study entitled “Molecular basis of target RNA cleavage by Cas13” elucidates the fundamental biochemical properties underpinning RSE’s specificity and efficiency. It also provides a comprehensive molecular characterization of Cas13’s interaction with RNA substrates, elucidating mechanisms essential to achieving precise target recognition and cleavage within complex cellular environments.

This pioneering research, supported by the Research Grants Council of the Hong Kong Special Administrative Region, represents a major leap forward in RNA therapeutics. It introduces a versatile platform capable of not only correcting genetic dysfunction at the RNA level but doing so in a manner that is tunable, reversible, and clinically practical. By circumventing permanent DNA alterations, RSE offers enhanced safety metrics while retaining high therapeutic efficacy.

The implications of RSE transcend neurodegenerative disorders, potentially influencing treatment strategies for a spectrum of RNA-related diseases including viral infections, genetic disorders, and malignancies characterized by aberrant RNA transcripts. As RNA biology and RNA-based medicine continue to evolve rapidly, this novel RNA editing technology could define the next frontier of precision molecular medicine.

Led by Professor Kwon Sung Chul and first authored by PhD candidate Joe Lam KC, the team’s breakthrough paves the way for a new generation of RNA-targeted interventions. As research progresses, the RSE platform promises to unlock innovative possibilities for managing previously intractable diseases by rewriting pathogenic RNA sequences with surgical precision, heralding a future where neurological degeneration may be halted or reversed through RNA therapy alone.

Subject of Research: Not applicable
Article Title: Molecular basis of target RNA cleavage by Cas13
News Publication Date: 8-Apr-2026
Web References: https://www.nature.com/articles/s41467-026-71578-7
References: 10.1038/s41467-026-71578-7
Keywords: RNA editing, Cas13, RNA Segment Editing (RSE), neurodegenerative diseases, Huntington’s disease, RNA therapeutics, gene expression, molecular scissors, RNA repair, biomedical innovation, RNA targeting, precision medicine